CHENGDU OLYMVAX BIOPHARMACEUTICALS financial statements, including revenue, expenses, profit, and loss
The total revenue of 688319 for the last quarter is 70.40 M CNY, and it's 50.63% lower compared to the previous quarter. The net income of Q1 24 is -26.00 M CNY.